Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK. (Q35332213)

7 August 2017

title

Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK. (English)

1 reference

7 August 2017

0 references

1 reference

YanGang Wang

1 reference

7 August 2017

WeiPing Liu

series ordinal

1 reference

7 August 2017

XiaoSheng He

series ordinal

1 reference

7 August 2017

Zhou Fei

series ordinal

1 reference

7 August 2017

publication date

1 March 2015

1 reference

Cell Biochemistry and Biophysics

7 August 2017

published in

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

page(s)

701-706

1 reference

CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Current therapeutic paradigms in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Temozolomide: mechanisms of action, repair and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Recent approaches to improve the antitumor efficacy of temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Mono- and sesquiterpenes and antifungal constituents from Artemisia species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Hispidulin induces apoptosis through mitochondrial dysfunction and inhibition of P13k/Akt signalling pathway in HepG2 cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Hispidulin sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by AMPK activation leading to Mcl-1 block in translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Hispidulin potently inhibits human glioblastoma multiforme cells through activation of AMP-activated protein kinase (AMPK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Gambogic acid enhances proteasome inhibitor-induced anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

AMPK regulation of the growth of cultured human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

AMP-activated protein kinase and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12013-014-0252-6

10.1007/S12013-014-0252-6

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference